NCT03956615 · ADVERSE EVENTS

Adverse events

sdAb-based TRNT of Multiple Myeloma: a Feasibility Study · Source last updated 2021-12-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 1 day
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma. Only 1 arm/group in this trial	0 / 10	0 / 10	0 / 10

Group identifiers: EG000: Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
10
description
Only 1 arm/group in this trial
id
EG000
other Num Affected
0
other Num At Risk
10
serious Num Affected
0
serious Num At Risk
10
title
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

frequency Threshold

time Frame

1 day

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice